The current study suggests that the expression of BMX acts as a prognostic indicator in its own right, in adult AML patients (the perceived target of ibrutinib, for whom more than 80% express elevated levels of Bruton’s tyrosinase kinase (BTK) [33]), as well as in paediatric AML patients. This evidence concerns the gene BMX and acute myeloid leukemia.